Markus Schaich

Murr, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology

Published: August 18, 2025

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 16, 2024

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.

Journal: The Lancet regional health. Europe

Published: July 19, 2024

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Journal: Blood advances

Published: April 03, 2024

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Journal: Haematologica

Published: February 06, 2024

An aggressive mediastinal EBV-associated large B cell lymphoma.

An aggressive mediastinal EBV-associated large B cell lymphoma.

Journal: Histopathology

Published: January 18, 2024

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.

Journal: The Lancet. Haematology

Published: January 08, 2024

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: September 22, 2023

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.

Journal: Leukemia

Published: May 28, 2023

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.

Journal: Blood cancer journal

Published: March 28, 2023

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.

Journal: British journal of cancer

Published: January 05, 2023

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.

Journal: Blood cancer journal

Published: November 27, 2022

Showing 1-12 of 69

Last Updated: 09/26/2026